Open AccessReal-World Eculizumab Dosing Patterns Among Patients with Paroxysmal Nocturnal Hemoglobinuria in a US Population
Author(s) -
Wendy Y. Cheng,
Sujata P. Sarda,
Nikita Mody-Patel,
Sangeeta Krishnan,
Mihran Yenikomshian,
Colin Kunzweiler,
Jensen Duy Vu,
Hoi Ching Cheung,
Mei Sheng Duh
Publication year - 2022
Publication title -
clinicoeconomics and outcomes research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.591
H-Index - 27
ISSN - 1178-6981
DOI - 10.2147/ceor.s346816
Subject(s) - eculizumab , paroxysmal nocturnal hemoglobinuria , medicine , dosing , cohort , dose , retrospective cohort study , population , pediatrics , anesthesia , immunology , antibody , environmental health , complement system
Current pharmacologic management of paroxysmal nocturnal hemoglobinuria (PNH) consists of C5 inhibitors, eculizumab and ravulizumab; however, because patients experience incomplete symptom control, off-label doses may be utilized. We conducted a retrospective, longitudinal cohort study of provider-based claims data to assess the real-world eculizumab dosing patterns in PNH patients.